Acute myelogenous leukemia with t(8;21) is a distinct clinicopathologic entity in which the malignant myeloblasts display a characteristic pattern of surface antigen expression. Quantitative analysis of surface marker expression in patients with this chromosomal abnormality compared to acute myelogenous leukemia patients with a different karyotype has not been reported. From 305 consecutive newly diagnosed acute myelogenous leukemia patients underwent immunophenotyping and cytogenetic analysis at our center; 16 patients (5.2%) had a t(8;21). Fluorescence intensity values were obtained, using a set of reference microbeads, by conversion of mean channel fluorescence to molecular equivalent of soluble fluorochrome. Patients with t(8;21) displayed higher levels of CD34, HLA-DR and MPO expression (Po0.001 for each) and lower levels of CD13 (P ¼ 0.03) and CD33 (P ¼ 0.02) expression. In order to study the sensitivity, specificity and predictive value of these markers, molecular equivalent of soluble fluorochrome thresholds were statistically determined. In patients with acute myelogenous leukemia (AML), t(8;21)(q22;q22) is a relatively frequent structural cytogenetic abnormality. This chromosomal translocation results in an in-frame fusion between the first 5 exons of the AML1 gene and essentially all of the ETO gene producing a chimeric protein.
In patients with acute myelogenous leukemia (AML), t(8;21)(q22;q22) is a relatively frequent structural cytogenetic abnormality. This chromosomal translocation results in an in-frame fusion between the first 5 exons of the AML1 gene and essentially all of the ETO gene producing a chimeric protein. 1 This protein, AML1-ETO, retains the ability of AML1 to heterodimerize with CBFb and to bind DNA as well as allowing ETO to interact with the N-Co-R/Sin3/HDAC complex. 2 This results in its acting as a negative dominant inhibitor of wild-type AML1. 3 The creation of AML1-ETO is necessary, but not sufficient, for leukemogenesis in AML with t(8;21). 4 The recently developed WHO classification of hematologic malignancies recognizes AML with t(8;21) as a distinct clinicopathologic entity. 5 This form of AML is found more frequently in children and young adults 6 and patients are predisposed to extramedullary localization. 7 Complete remission rates and long-term event-free survival are high, particularly when treatment incorporates high-dose cytosine arabinoside. 8 Histopathology characteristically demonstrates frequent type III myeloblasts, Auer rods, cytoplasmic vacuolization, pseudo-Chediak-Higashi granules, pink globules or salmon-colored cytoplasm, eosinophilia with abnormal granulation and granulocytic dysplasia. 6, 9, 10 Characteristic qualitative flow cytometry features have also been described in t(8;21) disease including a higher incidence of CD34, TdT, CD19 and CD56 expression as well as a lower incidence of CD33 expression. [11] [12] [13] We have shown that combined CD34, CD19 and CD56 positivity in AML patients has a 67% sensitivity, 100% specificity and a positive predictive value of 100% for the presence of t(8;21). 14 Despite support for the existence of a unique immunophenotype in AML with t(8;21), quantitative immunophenotyping in this form of AML has rarely been reported. 13 Recent reports have suggested that quantitative immunophenotyping may enhance the diagnosis of leukemias with specific cytogenetic abnormalities [15] [16] [17] and help define aberrant immunophenotyping patterns that could be useful for monitoring minimal residual disease. [17] [18] [19] It has also been suggested that quantitative immunophenotyping can contribute to our understanding of the pathogenesis of acute leukemia. 13, 15, 20 We undertook this prospective study of quantitative immunophenotyping to define whether there is a distinctive pattern in patients with AML and t(8;21).
Materials and methods

Patient Selection
Between January 1998 and June 2003, 327 adults with AML had a bone marrow sample referred to the Vancouver General Hospital for flow cytometry assessment. The diagnosis of AML was based upon standard FAB criteria. 21 We excluded from the analysis, 22 patients who did not have a bone marrow karyotype available from diagnosis because either cytogenetics were not performed (14 patients) or no analyzable metaphases were present (eight patients). Of the remaining 305 patients, 16 patients (5.2%) had evidence of t(8;21) on standard metaphase analysis. Quantitative immunophenotyping data from the 13 patients with t(8;21) was compared to the 292 patients lacking this abnormality.
Immunophenotyping
All immunophenotyping was performed on fresh bone marrow samples obtained at the time of diagnosis. The specimen was processed either by a whole blood lysis technique using hypotonic solution or by isolating the blast cells through density centrifugation and washing three times in PBS. The laser alignment was verified daily using DNA-Check and fluorescence was standardized using Standard-Brite beads (Coulter Inc, Hialiah, FL, USA). The cells were gated using CD45 vs side scatter gating method with the specimen being considered positive for a surface marker if Z20% of cells expressed the marker being tested. Coexpression of markers was assessed by a direct method in which different antibodies were added to a single sample tube.
Quantitative Analysis
To quantify the antigen fluorescence intensity, the mean channel fluorescence (MCF) values were converted into a molecular equivalent of soluble fluorochrome (MESF) using Quantum Simply Cellulart microbead kit (Flow Cytometry Standards Corporation, San Juan, Puerto Rico). The kit contained beads of five different fluorescence intensities producing five peaks on the flow cytometry histogram; one peak was a reference blank and the four others had predetermined MESF values. Instrument calibration for measurement of fluorescence intensity in MESF units was performed on a daily basis. The fluorescence beads were analyzed with the same instrument setting as those used for the analysis of the patient samples. After running the microbeads in the flow cytometer, a calibration plot to convert MCF to MESF was established. A linear regression equation correlating the channel number with a specific MESF value was calculated using Quickcalt software (Flow Cytometry Standards Corporation, San Juan, Puerto Rico).
Cytogenetic Analysis
Chromosome analysis was performed on bone marrow aspirates using standard 24-h culture and harvest procedures followed by G-banding, as previously reported. The karyotypes were reported according to published ISCN guidelines. 22 
Statistical Analysis
The mean and median MESF of each surface marker for patients with and without t(8;21) was calculated along with the standard deviation (s.d. ) and 95% confidence interval (CI). For the antigens that showed a difference in intensity between AML with t(8;21) and other AML patients, MESF thresholds that helped to distinguish between the two groups were devised. For this purpose, the classification 
Results
Qualitative Immunophenotyping
Qualitative immunophenotyping results for the patient cohort are summarized in Table 1 . Patients with t(8;21) showed a higher incidence of CD34 (P ¼ 0.02), TdT (P ¼ 0.003), CD19 (Po0.001) and CD56 (Po0.001) positivity and a lower incidence of CD33 positivity (P ¼ 0.002) compared to AML patients with other karyotypes.
Quantitative Immunophenotyping
Quantitative immunophenotyping results are summarized in Table 1 . AML patients with t(8;21) demonstrated a higher intensity of CD34 (Po0.001), HLA-DR (Po0.001), and MPO (Po0.001) expression compared to patients lacking t(8;21) (Figure 1 ). In addition, t(8;21) patients had a lower CD13 (P ¼ 0.025) and CD33 (P ¼ 0.02) intensity than other patients (Figure 1 ).
MESF Thresholds and Predictive Values
MESF thresholds that could distinguish between AML patients with t(8;21) and other AML patients were established by using CART analysis. These thresholds were set at MESF460. 5 Table 2 ). The sensitivity, specificity and predictive values for individual surface marker thresholds are shown in Table 2 . Each of these marker thresholds had a sensitivity of 100% with specificities of 62-92%. The predictive values for different quantitative marker threshold combinations are shown in Table 3 . Two combinations (CD34 and MPO; CD33 and MPO) had both a sensitivity and a positive predictive value of 100%.
Discussion
The surface antigens on hematopoietic cells that are studied by flow cytometry are differentiation proteins that are regulated in a coordinated way in normal hematopoiesis. 20 Leukemic hematopoiesis is characterized by asynchronous regulation of differentiation genes. 20 The quantitation of antigen density is an important tool to identify characteristics of these differentiation abnormalities and thereby provide insight into the pathogenesis of specific leukemia subtypes. 13, 15 Furthermore, the determination of aberrant phenotypic patterns can also allow for minimal residual disease (MRD) monitoring. 17, 19 AML with t(8;21) is characterized by a unique molecular abnormality, the AML1-ETO fusion gene. It has been shown that AML1-ETO protein can regulate the transcription of many genes important for hematopoiesis including the M-CSF receptor, the G-CSF receptor and BCL2 (all upregulated) as well as GM-CSF, TCR subunits (a, b and d), NP3 and MDR1 (all downregulated). 25 In addition, the AML1-ETO chimeric protein leads to dysplastic granulopoiesis in a knockin mice model. 26 Dysplastic granulopoiesis, a high density of G-CSF and M-CSF receptors and a low density of MDR1 have been noted in leukemic blasts with t(8;21). 10, [27] [28] [29] Collectively, these data suggest that in this unique form of AML, the phenotypic features probably result from intrinsic molecular alterations. It would follow that AML with t(8;21) could have a unique surface antigen expression pattern.
A correlation between the presence of t (8;21) and the qualitative expression of certain surface antigens on blast cells has previously been reported. [11] [12] [13] In these studies, it was found that AML with t(8;21) is characterized by a higher incidence of CD34, TdT, CD19 and CD56 positivity and a lower incidence of CD33 positivity. Our present study has confirmed these results and, in addition, provides a quantitative analysis of surface and cytoplasmic markers in this disease. To our knowledge, only one previous study has reported results of this type of analysis in AML with t(8;21). Porwit-MacDonald et al 13 found that AML with t(8;21) is associated with high intensity CD34 expression. The current study undertook a more comprehensive analysis of quantitative antigen expression in AML with t(8;21). It is now apparent that, in addition to CD34, this cytogenetic abnormality is associated with a higher intensity of HLA-DR and MPO expression as well as a lower intensity of CD13 and CD33 expression. 14 Although in our present series of patients this pattern had a sensitivity of only 62%, it retained a positive predictive value of 100% (data not shown). These results suggest that quantitative immunophenotyping may be better than qualitative immunophenotyping at predicting which patients with AML have a t(8;21) karyotype.
Although the incidence of AML with cryptic t(8;21) is relatively low, 30, 31 the detection of these cases has significant clinical relevance. AML with t(8;21) has a favorable prognosis and is often curable with consolidation chemotherapy alone. 8, 32 Patients may have a cryptic t(8;21) which can occur in patients with apparently normal (intermediate-risk) cytogenetics or in patients with complex (high-risk) karyotypes. 6, 9 Cytogenetics are frequently used to determine intensity of postremission therapy in AML and patients with either normal or high-risk karyotypes may be preferentially referred for allogenic bone marrow transplantation whereas goodrisk patients would not. In this regard, detection of a cryptic t(8;21) might result in the avoidance of more toxic therapies. While we did not perform molecular testing for an AML1-ETO fusion on patients who did not have t(8;21), all had flow cytometry screening. The consistency of our immunophenotyping findings suggests that very few patients could have (if any) a cryptic t(8;21) abnormality.
In normal hematopoiesis, progenitors expressing medium to high levels of CD34 antigen are characterized by absence or low expression of MPO. As the CD34 density decreases, the intensity of MPO increases. 33 A correlation between MPO and CD33 expression has also been observed in normal hematopoietic development and MPO-expressing cells have significantly stronger CD33 expression. 33 In this study, we defined at least two aberrant antigen intensity patterns: coexpression of CD34 
